The Relationships Between MASLD, Extrahepatic Multimorbidity, and All-Cause Mortality in the UK Biobank Cohort
The Journal of Clinical Endocrinology & Metabolism · 18.12.2025 · 111 (1) · e58-e69
DOI: 10.1210/clinem/dgaf342 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 10.06.2025. Verfasst von Qi Feng und 5 weiteren Autor:innen. Beteiligte Einrichtung: The George Institute for Global Health (UK), School of Public Health, Faculty of Medicine, Imperial College London, London W12 7RZ, UK. Hauptthemen laut MEDLINE: Fatty Liver, Metabolic Diseases. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, NIHR Biomedical Research Centre Funding Scheme, Imperial College London.
Abstract (Originalsprache)
Context
Metabolic dysfunction–associated steatotic liver disease (MASLD) affects one third of the world's population, but its associations with extrahepatic multimorbidity and mortality remain unclear.
Objective
This study aimed to estimate the impact of MASLD, with and without multimorbidity, on all-cause mortality.
Methods
We analyzed data from the UK Biobank. MASLD was identified as a fatty liver index ≥60 and presence of cardiometabolic risk factors. Multimorbidity was defined as ≥2 of the long-term conditions (LTCs) in a prespecified list of 47 extrahepatic conditions. Hazard ratios (HRs) from adjusted Cox models quantified the association between MASLD, multimorbidity and all-cause mortality.
Results
Of the 438 840 participants, 131 020 (29.9%) had MASLD at baseline. The participants with MASLD at baseline had a higher prevalence of multimorbidity than those without (21.3% vs 14.4%). In addition to cardiometabolic risk factors, MASLD was strongly associated with several LTCs, particularly metabolic, cardiovascular, cancers, kidney, mental/behavioral, and respiratory diseases. During a median follow-up of 13 years, MASLD was associated with higher mortality (HR 1.16; 95% CI 1.13, 1.19), with stronger associations in females and in those with low LTC counts (≤3 LTCs). Each additional LTC at baseline was associated with 30% and 38% higher mortality in MASLD (HR 1.30; 1.29, 1.32) and non-MASLD (HR 1.38; 1.37, 1.40) populations, respectively. Among the 47 LTCs, 16 were associated with increased mortality in people with MASLD.
Conclusion
Those with MASLD exhibited a higher prevalence of extrahepatic multimorbidity and a 16% higher rate of mortality than those without, underscoring the impact of liver steatosis on mortality and highlighting the need to target LTCs to improve outcomes and reduce health care burdens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The George Institute for Global Health (UK), School of Public Health, Faculty of Medicine, Imperial College London, London W12 7RZ, UK.
- Section of Investigative Medicine and Endocrinology, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London W12 0NN, UK.
- Department of Medicine, Division of Liver Diseases, The Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
- Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London W12 0NN, UK.
- Department of Hepatology, St Mary's Hospital, Imperial College Healthcare NHS Trust, London W2 1NY, UK.
- The George Institute for Global Health (Australia), University of South New Wales, Sydney, NSW 2000, Australia.
ORCID-Profile: Qi Feng, Mark Woodward
Förderung
- Medical Research Council
- NIHR Biomedical Research Centre Funding Scheme
- Imperial College London
- NCI NIH HHS
- Imperial Clinical Research Facility
- MRC
- Imperial College Healthcare NHS Trust
- Clinician Scientist
Zitieren
APA
Feng, Q., Izzi-Engbeaya, C. N., Branch, A. D., Mullish, B. H., Manousou, P., & Woodward, M. (2025). The Relationships Between MASLD, Extrahepatic Multimorbidity, and All-Cause Mortality in the UK Biobank Cohort. The Journal of Clinical Endocrinology & Metabolism, 111(1), e58-e69. https://doi.org/10.1210/clinem/dgaf342
Vancouver
Feng Q, Izzi-Engbeaya CN, Branch AD, Mullish BH, Manousou P, Woodward M. The Relationships Between MASLD, Extrahepatic Multimorbidity, and All-Cause Mortality in the UK Biobank Cohort. The Journal of Clinical Endocrinology & Metabolism. 2025;111(1):e58-e69. doi:10.1210/clinem/dgaf342
BibTeX
@article{Feng2025,
author = {Feng, Qi and Izzi-Engbeaya, Chioma N and Branch, Andrea D and Mullish, Benjamin H and Manousou, Pinelopi and Woodward, Mark},
title = {The Relationships Between MASLD, Extrahepatic Multimorbidity, and All-Cause Mortality in the UK Biobank Cohort},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
volume = {111},
number = {1},
pages = {e58--e69},
doi = {10.1210/clinem/dgaf342}
}
EUVIMED